Spero Therapeutics Inc. (SPRO)
Spero Therapeutics Inc. (SPRO) Stock Price, Analysis & Data
| Bid | 0.85 |
| Market Cap | 71.92M |
| Revenue (ttm) | 47M |
| Net Income (ttm) | 7.38M |
| Beta | 1.48 |
| EPS (ttm) | 0.14 |
| PE Ratio (ttm) | 8.82 |
| Forward PE | -1.11 |
| P/B (ttm) | 1.35 |
| P/S (ttm) | 1.53 |
| Earnings Date | Nov 12, 2026 |
| Ask | 1.52 |
| Volume | 299,242 |
| Avg. Volume (20D) | 1,606,167 |
| Open | 1.20 |
| Previous Close | 1.20 |
| Day's Range | 1.19 - 1.24 |
| 52-Week Range | 1.08 - 3.08 |
| Analyst | n/a |
| Price Target | 4 (225.20%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has comple...
Financial Performance
In 2025, Spero Therapeutics's revenue was 59.62M, an increase of 117.62% compared to the previous year's 27.4M. Earnings were 8.57M, a decrease of -112.5%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for SPRO stock is "null". The 12-month stock price forecast is 4, which is upside of 225.2% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
